Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Price Target from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen brokerages that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $30.56.

Several analysts recently commented on the company. Wedbush reaffirmed a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Scotiabank dropped their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Truist Financial dropped their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. Finally, HC Wainwright lowered their price target on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new position in shares of Keros Therapeutics in the second quarter valued at approximately $1,400,000. AlphaQuest LLC lifted its position in shares of Keros Therapeutics by 96.1% in the second quarter. AlphaQuest LLC now owns 25,958 shares of the company's stock valued at $347,000 after acquiring an additional 12,724 shares in the last quarter. CWM LLC increased its holdings in shares of Keros Therapeutics by 87.5% in the second quarter. CWM LLC now owns 5,000 shares of the company's stock valued at $67,000 after purchasing an additional 2,333 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Keros Therapeutics in the second quarter valued at approximately $348,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Keros Therapeutics by 56.0% in the second quarter. Assenagon Asset Management S.A. now owns 101,297 shares of the company's stock valued at $1,352,000 after purchasing an additional 36,360 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Price Performance

Keros Therapeutics stock remained flat at $14.32 during trading hours on Thursday. The company's stock had a trading volume of 261,048 shares, compared to its average volume of 448,280. The firm's 50-day moving average price is $14.05 and its 200 day moving average price is $12.69. The firm has a market capitalization of $581.68 million, a PE ratio of -79.56, a price-to-earnings-growth ratio of 2.59 and a beta of 1.33. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. During the same period last year, the company earned ($1.21) earnings per share. Sell-side analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.